ArticleJournal of medical virology2020
Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.
Article in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Diagnostic performance of COVID-19 serological assays during early infection: A systematic review and meta-analysis of 11 516 samples.Influenza and other respiratory viruses · 2021Pooled it
- Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data.Cancer letters · 2021Pooled it
- The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.Life sciences · 2020Pooled it
- Pooled it
- Clinical outcomes of Omicron infection and vaccine acceptance among pediatric liver transplant recipients: insights from a cross-sectional survey.Virology journal · 2024Observational
- How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?Stem cell reviews and reports · 2023Review
- Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis.Inflammation and regeneration · 2022Review
- COVID-19-Associated Large- and Medium-Sized-Vessel Pathology: A Case Series.Aorta (Stamford, Conn.) · 2022Article
- Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: a systematic review of evidence to support global policy-level actions and research.Global health journal (Amsterdam, Netherlands) · 2022Review
- SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.International journal of molecular sciences · 2022Review
- Characteristics and Prognosis of Antibody Non-responders With Coronavirus Disease 2019.Frontiers in medicine · 2022Article
- SARS-CoV-2 vaccination in androgen sensitive phenotypes - A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients.Frontiers in immunology · 2022Article
- A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV.Frontiers in medicine · 2022Article
- Respiratory Mucosal Immunity: Kinetics of Secretory Immunoglobulin A in Sputum and Throat Swabs From COVID-19 Patients and Vaccine Recipients.Frontiers in microbiology · 2022Article
- Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.Current neuropharmacology · 2022Article
- Advances in the design and development of SARS-CoV-2 vaccines.Military Medical Research · 2021Review
- Transmission dynamics and successful control measures of SARS-CoV-2 in the mega-size city of Guangzhou, China.Medicine · 2021Article
- Molecular Insights into the Crosstalk Between Immune Inflammation Nexus and SARS-CoV-2 Virus.Current microbiology · 2021Review
- COVID-19 seroprevalence among hospital staff and preprocedural patients in Thai community hospitals: a cross-sectional study.BMJ open · 2021Article
- COVID and Lung Cancer.Current oncology reports · 2021Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms, and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SARS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in nonsevere cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.